Cited by

• Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial.

  Pedersen-Bjergaard U, Agesen RM, Brøsen JMB, Alibegovic AC, Andersen HU, Beck-Nielsen H, Gustenhoff P, Hansen TK, Hedetoft C, Jensen TJ, Juhl CB, Jensen AK, Lerche SS, Nørgaard K, Parving HH, Sørensen AL, Tarnow L, Thorsteinsson B. Pedersen-Bjergaard U, et al. Diabetes Obes Metab. 2022 Feb;24(2):257-267. doi: 10.1111/dom.14574. Epub 2021 Nov 2. Diabetes Obes Metab. 2022. PMID: 34643020 Free PMC article. Clinical Trial.
• Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3.

  Bonadonna RC, Yale JF, Brulle-Wohlhueter C, Boëlle-Le Corfec E, Choudhary P, Bailey TS. Bonadonna RC, et al. Diabetes Obes Metab. 2019 Mar;21(3):715-719. doi: 10.1111/dom.13578. Epub 2018 Dec 9. Diabetes Obes Metab. 2019. PMID: 30414260 Free PMC article. Clinical Trial.
• The effect of insulin analogs in people with type 1 diabetes at increased risk of severe hypoglycemia.

  Broeng-Mikkelgaard S, Brøsen JMB, Kristensen PL, Thorsteinsson B, Pedersen-Bjergaard U. Broeng-Mikkelgaard S, et al. Front Pharmacol. 2023 Nov 27;14:1301931. doi: 10.3389/fphar.2023.1301931. eCollection 2023. Front Pharmacol. 2023. PMID: 38089060 Free PMC article. Review.
• A Cross-Sectional Study of Quality of Life Among Brazilian Adults With Type 1 Diabetes Treated With Insulin Glargine: Findings and Implications.

  Almeida PHRF, Godman B, Dos Santos Nunes-Nogueira V, de Lemos LLP, de Assis Acúrcio F, Guerra-Junior AA, de Araújo VE, Almeida AM, Alvares-Teodoro J. Almeida PHRF, et al. Clin Diabetes. 2022 Summer;40(3):312-326. doi: 10.2337/cd21-0068. Clin Diabetes. 2022. PMID: 35983417 Free PMC article.